We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Is President Donald Trump on a Collision Course With History? More Than a Century of Data Paints a Clear Picture. Does Warren Buffett Know Something Wall Street Doesn't? He Just Made a Shocking ...
Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company reported sales of $627.7 ...
Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by ...
Neurocrine Biosciences exceeded earnings expectations ... in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental ...
Neurocrine's Phase 3 pipeline is also set to ... we have that came out of the Phase 2 program and quite frankly, so was Takeda. As we've seen from Takeda over the past several years, they've ...